NasdaqGS:ENTABiotechs
Enanta Pharmaceuticals (ENTA) Is Up 33.3% After Positive Phase 2b RSV Results Propel Zelicapavir Forward
In late September 2025, Enanta Pharmaceuticals announced positive topline results from its Phase 2b trial of zelicapavir for treating respiratory syncytial virus (RSV) in high-risk adults, observing faster symptom resolution and a lower hospitalization rate despite not meeting the trial's primary endpoint.
This proof-of-concept success provides the company with clear support to advance zelicapavir into Phase 3 development, potentially addressing significant unmet needs in the RSV market for...